Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.10. | IN BRIEF: SkinBioTherapeutics boosts financial 2025 turnover forecast | 2 | Alliance News | ||
23.10. | SkinBioTherapeutics - Integration update and share price movement | - | RNS | ||
16.10. | SkinBioTherapeutics - Issue of Equity and Total Voting Rights | 1 | RNS | ||
11.10. | AIM WINNERS & LOSERS: SkinBioTherapeutics and Oxford Metrics make buys | 3 | Alliance News | ||
11.10. | SkinBioTherapeutics shares jump on acquisition of topical cream maker | 5 | Sharecast | ||
11.10. | SkinBioTherapeutics - Acquisition and Financial Update | 1 | RNS | ||
04.10. | SkinBioTherapeutics - Notice of Investor Meet Company Presentation | 1 | RNS | ||
19.09. | SkinBioTherapeutics reports positive results from testing with Croda | 4 | Sharecast | ||
19.09. | AIM WINNERS & LOSERS: SkinBioTherapeutics gets Croda positive feedback | 4 | Alliance News | ||
19.09. | SkinBioTherapeutics - Final testing of SkinBiotix by Croda completed | 2 | RNS | ||
02.08. | SkinBioTherapeutics secures £1.56m from new investors | 2 | Sharecast | ||
02.08. | SkinBioTherapeutics lands GBP1.6 million investment to support growth | 1 | Alliance News | ||
02.08. | SkinBioTherapeutics - Investment of £1.56m from new investors | 1 | RNS | ||
29.07. | SkinBio says trading "better than expected" as revenue grows | 1 | Alliance News | ||
29.07. | SkinBioTherapeutics reports better-than-expected full-year trading | 1 | Sharecast | ||
29.07. | SkinBioTherapeutics - Appointment of Senior Croda VP as Board Advisor | 1 | RNS | ||
29.07. | SkinBioTherapeutics - Full year trading update | 1 | RNS | ||
23.07. | SkinBio announces closure of its convertible bond facility | 1 | Alliance News | ||
23.07. | SkinBioTherapeutics - Closure of Convertible Bond Facility | 1 | RNS | ||
22.07. | SkinBioTherapeutics - Conversion Notice and Total Voting Rights | - | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
DESTINY PHARMA | 0,048 | 0,00 % | JP Jenkins Ltd: Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula | JP Jenkins Ltd
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative... ► Artikel lesen | |
QIAGEN | 39,730 | +1,74 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
ADMA BIOLOGICS | 19,245 | +18,00 % | ADMA Biologics jumps as KPMG becomes new auditor | ||
EVOTEC | 7,145 | +0,78 % | Aixtron, BB Biotech, Evotec, HelloFresh, Stabilus, TUI - 4investors Aktien Top-New | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,120 | +3,08 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,68 | -0,08 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
BIONTECH | 102,40 | -0,87 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 9,160 | +22,30 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
NUVALENT | 88,46 | -0,03 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results | Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET / 2:30 p.m. CEST
$658.0 million in cash, cash equivalents and marketable... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,435 | +1,82 % | Recursion Pharmaceuticals-Direktor Blake Borgeson verkauft Aktien im Wert von 76.926 US-Dollar | ||
SUMMIT THERAPEUTICS | 18,860 | +1,45 % | Summit Therapeutics Aktie: Bleiben Sie wachsam! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnete am 26. Oktober 2024 einen bemerkenswerten Kursanstieg von 9,25% auf 21,26 USD. Dieser Aufschwung erfolgt trotz einer herausfordernden... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 42,100 | -0,38 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
VERA THERAPEUTICS | 43,500 | +7,73 % | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 47,100 | +5,87 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 |